Livestock firm Genus ramps up R&D spend
in gene editing race
Send a link to a friend
[May 21, 2016]
By Ben Hirschler
LONDON (Reuters) - British animal genetics
firm Genus is diving deeper into the hot area of gene editing, in a move
Chief Executive Karim Bitar says will bring long-term gains at the cost
of a hefty hike in research spending.
|
|
The company, which sells pig and bull semen to farmers worldwide,
has signed an exclusive global deal with privately owned Caribou
Biosciences to use the U.S. firm's CRISPR/Cas9 technology to develop
pig and cattle breeds.
"The increase in investment will be substantial," Bitar said in an
interview on Wednesday, after announcing the collaboration. "We've
been spending about 7 percent of sales on R&D ... that's definitely
going up."
Genus has invested $5 million in Caribou and will make an
unspecified upfront payment to access its technology, as well as
funding a four-year research program.
The latest tie-up builds on Genus's existing work with the
University of Missouri using gene editing, which led to the breeding
of the world's first pigs resistant to a common viral disease in
December.
Bitar said the investment in gene editing at Genus would run into
"millions of pounds" and the company's current overall annual
research and development budget of around 30 million pounds ($44
million) would increase at a double-digit rate in the year from July
1.
"In the next financial year, the R&D spending will clearly be
increasing by over 10 percent. It's going to be meaningful for us."
In the long term Genus expects a commensurate return on its
investment by producing new animal breeds that are resistant to
diseases and offer improved protein yields.
Gene editing allows targeted cuts to DNA using biological "scissors"
that operate a bit like a word-processing program that can find and
replace selected stretches of genetic code.
[to top of second column] |
The technology holds out great promise for treating human diseases,
and improving agricultural crops and animal species.
The challenge for Genus in the coming years will be to balance
higher investment against the need to maintain investor returns.
"I think the reality is that we are going to continue to grow our
earnings because the business is performing strongly at the moment,"
Bitar said. "It's going to be a balancing act in terms of the degree
of earnings growth - that's something we are evaluating."
($1 = 0.6872 pounds)
(Editing by Greg Mahlich)
[© 2016 Thomson Reuters. All rights
reserved.]
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|